To gain a better understanding of the newly available options for patients with this hematologic malignancy, Journal of Clinical Pathways spoke with Natalie S Callander, MD, professor of hematology/oncology at University of Wisconsin School of Medicine and Public Health (Madison, WI).
Journal of Clinical Pathways recently spoke with Dr Page about the continued validation of the VeriStrat test, the role of testing within clinical pathways, and their effect on the OCM.
Journal of Clinical Pathways spoke with Editorial Advisory Board member Ayman Elfiky, MD, MSc, MPH, about how clinical pathways are used at Dana-Farber Cancer Institute (Boston, MA).
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker.
To best understand how a large research hospital implements clinical pathways in day-to-day practice, Journal of Clinical Pathways spoke with Editorial Advisory Board Member David A Hughes, who serves as the director of the clinical pathways program at Seattle Cancer Care Alliance.
Journal of Clinical Pathways spoke with Jennifer Singleterry, MA about the role of financial navigators in the oncology landscape and strategies for greater global insurance literacy across the spectrum.
In order to better understand the role that value plays in clinical pathways, Journal of Clinical Pathways spoke with Alexander W Bastian, MBA, a member of the journal’s Editorial Advisory Board.
Clinical pathway implementation and adaptation requires proper leadership and appreciation of the nuances of organizations and patient populations, according to Aymen Elfiky, MD.
Clinical pathways are likely to serve as a valuable tool in the transition to a value-based system of care and may also serve as potential leverage in policy regarding delivery reform, according to Robin Zon, MD.
Brian D Weiss discusses the continued potential for improvement science's utility across the field of childhood cancer treatment.